By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Breckenridge Pharmaceutical, Inc. 

1141 S. Rogers Circle
Suite 3
Boca Raton  Florida  33487  U.S.A.
Phone: 800-367-3395 Fax: 561-989-9747


SEARCH JOBS


Industry
Pharmaceutical






Company News
Breckenridge Pharmaceutical, Inc. Announces Approval For Duloxetine Delayed-Release Capsules 6/13/2014 10:48:04 AM
Pernix Therapeutics, Inc. (PTX) Completes Divesture of Non-Core Assets to Breckenridge Pharmaceutical, Inc. 9/12/2013 10:06:56 AM
Breckenridge Pharmaceutical, Inc. Completes Acquisition of Certain Cypress Products From Pernix Therapeutics, Inc. (PTX) 9/12/2013 9:10:13 AM
Breckenridge Pharmaceutical, Inc. Buys Certain Cypress Pharmaceutical Assets From Pernix Therapeutics, Inc. (PTX) for $30 Million 8/9/2013 6:40:51 AM
Breckenridge Pharmaceutical, Inc. Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macoven's Discontinuance of Certain Products 7/10/2013 8:54:55 AM
Breckenridge Pharmaceutical, Inc. Announces Approval of Rizatriptan Benzoate ODT (Orally Disintegrating Tablets) 7/3/2013 10:50:59 AM
Breckenridge Pharmaceutical, Inc. Announces Paragraph IV ANDA Litigation with Par Pharmaceutical, Inc. & Alkermes Pharma Ireland Limited for Its ANDA Megestrol Acetate Oral Suspension (Megace® ES) 6/28/2013 10:27:14 AM
Breckenridge Pharmaceutical, Inc. Signs Letter of Intent With Welding GmbH & Co & SK Chemicals 6/11/2013 8:30:17 AM
Breckenridge Pharmaceutical, Inc. Announces Agreement with Aptalis Pharmatech to Market Propranolol Hydrochloride Extended-Release Capsules 3/26/2013 11:13:55 AM
Breckenridge Pharmaceutical, Inc. Announces Approval for Pioglitazone Hydrochloride Tablets 2/14/2013 8:35:14 AM
1234
//-->